# Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

> **NCT00151060** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Estramustine
- **DRUG:** Etoposide
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00151060
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-12
- **Primary completion:** 2004-11
- **Final completion:** 2006-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2015-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151060, "Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00151060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*